BioSpace News Archive

Continuing a shared commitment to innovation, Compass Group, the world’s largest food and facility services company, and AstraZeneca, the global, science-led, patient-focused pharmaceutical company, are taking supplier management to the next level.

Milestone Pharmaceuticals Inc. today reported financial results for the fourth quarter and year ended December 31, 2022 and provided a clinical and corporate update.

Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (“Coeptis” or “the Company”), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced it has obtained the exclusive right to negotiate towards the acquisition of VyGen-Bio, Inc. or its assets.

C2N Diagnostics today announced the Annals of Clinical and Translational Neurology has published online a new study that further demonstrates the Amyloid Probability Score (APS), used in the company’s PrecivityAD® blood test to help healthcare providers better diagnose Alzheimer’s Disease (AD), is a reliable marker of brain amyloidosis among individuals aged 60 years and older with cognitive impairment (current Intended Use population).

Boehringer Ingelheim reported a strong performance in 2022, a year in which 30 million patients benefited from its innovative medicines, while deepening investments in the search for new treatments.

Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced that the first patient was dosed in a phase 1 multicenter, open label, first-in-human dose escalation study of the innate cell engager AFM28 monotherapy in patients with CD123-positive relapsed/refractory acute myeloid leukemia.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Commission (EC) approved Libtayo ® in combination with platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with ≥1% PD-L1 expression.

Lavie Bio Ltd. today is pleased to announce the appointment of Mr. Amit Noam as Chief Executive Officer (“CEO”) of Lavie Bio, effective as of April 16, 2023.

Nevro Corp. today announced that the company will report its financial results for the first quarter ended March 31, 2023 after the market closes on April 26, 2023.

CollPlant Biotechnologies today announced financial results for the full year ended December 31, 2022 and provided a corporate update on its programs.